Secondly, the contingency-fee system, whereby plaintiffs do not pay anything if they lose and the lawyers take a proportion of the damages (usually between a third and a half) if they win, means that more cases are started. Thirdly, punitive damages may be awarded in some cases, which may mean enormous payments. Fourthly, the welfare state is less developed than in Britain, which means that injured individuals may look to the courts to compensate them for items such as medical expenses. Fifthly, the Freedom of Information Act gives access to information that might not be available in England.
Nevertheless, the United States is the home of strict liability in tort, and only there can we find a fully developed tort system of compensating injured people-and that is the system that Britain and Europe are choosing to adopt. Perhaps what we see there will encourage us to look to New Zealand, which has one of the few no-fault systems of accident compensation. In a no-fault system the injured person is compensated from a fund without having to take legal action against anybody. In New Zealand a central fund is administered by the Government.
Submerged principles
Each society arrives at its own system for compensating people injured by products. These systems depend on the way that the societies answer certain fundamental questions: too often these fundamental questions are submerged under legal and administrative complexities. The next article will consider American experience more specifically, but I want here to discuss some of the underlying questions.
Is it right that a young woman who has pelvic cancer which is said to be caused by diethylostilboestrol (DES) should receive $500 000 
Fourthly, some companies may be forced into bankruptcy or trade without insurance (though there is no evidence that this has happened to drug companies).
Causation and compensation
The problem of causation is crucial in all legal liability, but particularly in the case of liability for drug injury. If some people are to receive several hundred thousand dollars compensation for a cancer caused by a drug, yet other people with the same cancer but no obvious cause are to receive nothing, there is a strong incentive for the person with no cause to try to find one. Many drugs have adverse reactions that are the same as naturally occurring disease; indeed, doctors may realise that a drug has such a reaction only after statistical analysis. The classic example, but there are many thousands of others, is a woman on the contraceptive pill who has a stroke. How can anybody decide whether that stroke was "caused" by the pill? Nobody can, nor can anybody decide how important were the facts that she smoked and was overweight and hypertensive.
Although a woman taking the pill who has a stroke is the example commonly used to illustrate the problems of causation, in many ways it is a poor one. A stroke is a well-known adverse reaction to the pill and manufacturers will provide warnings about it. The problem of causation is more important when somebody thinks he can link an unexplained illness to a drug. The best example of this kind of wrangle over causation is with the antinauseant drug Debendox (sold as Bendectin in the United States). This drug is alleged to cause malformations in the babies of mothers who take it during pregnancy. Despite large studies showing no overall increase in the incidence of malformations in the children of women who took the drug in early pregnancy, the court-and the jury-may well be swayed by persuasive argument when about to decide whether a particular child was injured by the drug.
This problem of causation persists through almost all compensation systems. Only in a system where money was paid to all who had strokes, all babies born with malformations, or, indeed, anybody suffering any ill would the problem be avoided. The National Health Service and the social security system come close to being such systems, but a so-called no-fault compensation system such as the one in New Zealand compensates only those injured in accidents. Thus a child born with a malformation caused by a drug might be eligible for compensation but not one whose malformation was just "one of those things."
Compensation through the courts can never result in each injured person receiving benefits "according to his need." Only a change in social attitudes followed by legislation backed up by adequate funds could achieve such an equitable system. The courts have done their best to help the injured people who come their way, but few problems have been solved and many have been created. The next article will consider how American product liability law has developed and a third will consider American attempts to improve the compensation system and compare these with European attempts to do the same thing.
As three-month colic appears to be commoner in breast-fed infants might this serve as a protective function in the young animal, encouraging suckling and clinging in the early days of extrauterine life ? Is there some substance in breast milk that stimulates smooth muscle and is inhibited by suckling or some other secretion ? Levine and Bell' wrote 30 years ago that evening colic was sometimes relieved by the use of a "pacifier" or "dummy," and mnight therefore represent "an unsatisfied need for adequate oral gratifications." I have been unable to confirm this. I have the clinical impression, which I have not confirmed statistically, that evening colic is more common in breast-fed babies. I wonder whether prostaglandins, present in considerable quantities in human niilk,2 some of them known to be related to contraction of smooth muscle, or one or more of the 200 or so gut hormones,3 such as motilin, neurotensin, pancreatic polypeptides, and enteroglucagon, significantly different in breast-fed and bottle-fed babies, may be related to evening colic. I believe that before long research on the above will solve the riddle of evening colic. Somehow the solution must fit in with the relief that the anticholinergic drug dicyclomine hydrochloride invariably provides4 5 in babies with symptoms typical of the condition.
Are pigeons roosting around buildings a health hazard to the occupants?
Pigeons roosting around buildings are probably more a nuisance than a health hazard, although they may be carriers of certain diseases communicable to man. One of these is psittacosis or ornithosis, which is caused by a virus-like micro-organism and is often associated with members of the parrot family, although it also occurs in pigeons, chickens, ducks, and pheasants. It has been estimated that 90% of the pigeons in Trafalgar Square are carriers of the organism without showing any apparent signs of the disease. During 1945-65, 100 human cases of acute respiratory infections with organisms of the psittacosis group were seen in South Bedfordshire and North Hertfordshire. Such infections often occur among pigeon fanciers.' Railway guards have been infected from racing pigeons in crates in their vans,2 and as many as 500 cases ofhuman psittacosis, 19 of them fatal, may have been caused by the breeding and transport of racing pigeons.3 Yet the pigeon strain of the organism is probably not very virulent to man, and there is no evidence of tourists becoming infected in Trafalgar Square, though they may well be breathing the organisms in aerosol concentrations.4 Nevertheless, airborne infections to people from heavy densities of pigeons might be possible. The control of the number of pigeons in city and urban localities is the responsibility of the local government authority.
